Baidu
map

Science:VirScan可揭示一个人完整的病毒接触史

2015-06-05 coo 生物360

一种叫做VirScan的新技术只需不到一滴血的量便能确定一个人在其一生中所接触过的所有病毒。研究人员对来自世界各地569人使用了该筛检技术并发现,平均而言,他们的实验参与者在其一生中接触过大约10种病毒。VirScan为研究人类病毒组(已知会感染人的各种病毒汇集)和免疫系统(它会因接触病毒而永久性地改变)之间的相互作用提供了一个强有力而且廉价的工具。在此之前,用来检测病毒遗留下来的无法抹灭足迹的血

一种叫做VirScan的新技术只需不到一滴血的量便能确定一个人在其一生中所接触过的所有病毒。研究人员对来自世界各地569人使用了该筛检技术并发现,平均而言,他们的实验参与者在其一生中接触过大约10种病毒。

VirScan为研究人类病毒组(已知会感染人的各种病毒汇集)和免疫系统(它会因接触病毒而永久性地改变)之间的相互作用提供了一个强有力而且廉价的工具。在此之前,用来检测病毒遗留下来的无法抹灭足迹的血液化验(即免疫系统所分泌的抗体)受到了其所能筛检病毒数目的限制。

为了扩大这些化验所能涵盖的范围,George Xu和同事用采自206种病毒的一个大型病毒肽数据集(它代表了1000多不同的病毒株)创建了一个所有人类病毒肽的综合代表。用这一模板,他们能筛检血样本中的病毒抗体,而每个样本的筛检价格只要25美元。这些来自不同研究参与者(他们来自4个不同的大陆)的样本揭示了超过1.06亿种肽-抗体相互作用。多人接触过大约10种病毒,但至少有一些志愿者接触过84种病毒。

这些发现凸显了保守的免疫应答(或称“公共抗原表位”)并表明个人可能会因应相同的病毒而分泌类似的抗体--尽管人们接触病毒的比率是大相径庭的。Xu和他的同事提出,VirScan的精度可用更多的血样本来提高,且未来它可能还会适用于细菌、真菌或原生动物。

原始出处:

George J. Xu1,2,3,4,*, Tomasz Kula3,4,5,*, Qikai Xu3,4, Mamie Z. Li3,4, Suzanne D. Vernon6, Thumbi Ndung’u7,8,9,10, Kiat Ruxrungtham11, Jorge Sanchez12, Christian Brander13, Raymond T. Chung14, Kevin C. O’Connor15, Bruce Walker8,9, H. Benjamin Larman16, Stephen J. Elledge3,4,6,†.Comprehensive serological profiling of human populations using a synthetic human virome.Science, June 5, 2015.DOI: 10.1126/science.aaa0698

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=105983, encodeId=b4261059833d, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:41:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26748, encodeId=b79026e48c0, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:56:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375053, encodeId=5cee13e505343, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 07 00:41:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26053, encodeId=302026053bd, content=新进展啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d631623611, createdName=huangjianhuang, createdTime=Fri Jun 05 13:20:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26054, encodeId=a55b2605415, content=新进展啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d631623611, createdName=huangjianhuang, createdTime=Fri Jun 05 13:20:00 CST 2015, time=2015-06-05, status=1, ipAttribution=)]
    2016-08-27 李东泽

    这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=105983, encodeId=b4261059833d, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:41:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26748, encodeId=b79026e48c0, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:56:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375053, encodeId=5cee13e505343, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 07 00:41:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26053, encodeId=302026053bd, content=新进展啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d631623611, createdName=huangjianhuang, createdTime=Fri Jun 05 13:20:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26054, encodeId=a55b2605415, content=新进展啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d631623611, createdName=huangjianhuang, createdTime=Fri Jun 05 13:20:00 CST 2015, time=2015-06-05, status=1, ipAttribution=)]
    2015-06-09 huaxipanxing

    看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=105983, encodeId=b4261059833d, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:41:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26748, encodeId=b79026e48c0, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:56:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375053, encodeId=5cee13e505343, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 07 00:41:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26053, encodeId=302026053bd, content=新进展啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d631623611, createdName=huangjianhuang, createdTime=Fri Jun 05 13:20:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26054, encodeId=a55b2605415, content=新进展啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d631623611, createdName=huangjianhuang, createdTime=Fri Jun 05 13:20:00 CST 2015, time=2015-06-05, status=1, ipAttribution=)]
    2015-06-07 jichang
  4. [GetPortalCommentsPageByObjectIdResponse(id=105983, encodeId=b4261059833d, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:41:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26748, encodeId=b79026e48c0, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:56:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375053, encodeId=5cee13e505343, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 07 00:41:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26053, encodeId=302026053bd, content=新进展啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d631623611, createdName=huangjianhuang, createdTime=Fri Jun 05 13:20:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26054, encodeId=a55b2605415, content=新进展啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d631623611, createdName=huangjianhuang, createdTime=Fri Jun 05 13:20:00 CST 2015, time=2015-06-05, status=1, ipAttribution=)]
    2015-06-05 huangjianhuang

    新进展啊

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=105983, encodeId=b4261059833d, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:41:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26748, encodeId=b79026e48c0, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:56:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375053, encodeId=5cee13e505343, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 07 00:41:00 CST 2015, time=2015-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26053, encodeId=302026053bd, content=新进展啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d631623611, createdName=huangjianhuang, createdTime=Fri Jun 05 13:20:00 CST 2015, time=2015-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26054, encodeId=a55b2605415, content=新进展啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d631623611, createdName=huangjianhuang, createdTime=Fri Jun 05 13:20:00 CST 2015, time=2015-06-05, status=1, ipAttribution=)]
    2015-06-05 huangjianhuang

    新进展啊

    0

相关资讯

Cell Host Microbe:I型干扰素b的病毒清除机制研究

I型干扰素在宿主抵抗微生物感染的先天免疫与后天免疫过程中都具有重要的作用。包括控制病原体的状态,调节先天免疫反应,激活后天免疫反应等等。尽管如此,一些研究发现I型干扰素能够提高感染的严重程度。之前的研究发现I型干扰素的阻断能够促进病毒感染后的清除,而这一效应主要是通过营造免疫抑制的环境实现的,主要包括:1、促进一些负向调控因子,如IL-10,PD-1的产生;2、破坏脾脏的结构;3,抑制淋巴细胞

mBio:研究发现埃博拉病毒的致命弱点

最近,一个国际研究小组(包括来自美国叶史瓦大学阿尔伯特爱因斯坦医学院和美国陆军传染病医学研究所的科学家),发现了致命埃博拉病毒要进入细胞必须打开的分子“锁”。这项研究是在小鼠中进行的,表明阻断进入这把分子锁的药物,可以防御埃博拉病毒感染。相关研究结果发表在今天出版的在线期刊 mBio 上。研究人员发现,埃博拉病毒不能感染细胞,除非它首先连接到细胞深处膜隔间(称为溶酶体)中的一个宿主蛋白,称为Nie

CRISPR技术剪掉HIV病毒基因,根治艾滋病

艾滋病病毒是一种高效且多变的逆转录病毒。一旦病毒将其DNA插入宿主细胞的基因组,它即拥有很长的潜伏期,可以保持休眠和隐匿状态达数年之久。 虽然医生可以通过多种不同的抗逆转录病毒药物搭配使用的鸡尾酒疗法来控制病毒,但若停止治疗,病毒即可恢复活力。 为了使潜伏中的艾滋病病毒失活,马萨诸塞大学医学院(University of Massachusetts Medical School

Nature:siRNA干预治疗埃博拉病毒感染新进展

埃博拉病毒在西非地区的流行仍未得到有效控制,其造成的病例和死亡比之前的病毒爆发流行都要严重,是一次前所未有的大灾难。近日,著名国际学术期刊nature在线发表了美国科学家关于埃博拉病毒治疗进展的相关研究。   在此研究之前,科学家们已经研发出一些病毒接触后干预手段,对返回欧洲和美国的病人进行治疗。但这些治疗手段对于治疗埃博拉病毒新暴发亚型的体内疗效仍未可知。   在该项

Lancet Infect Dis:乌干达埃博拉病毒造成的长期后遗症

背景:长期埃博拉病毒疾病健康结果有限的可用数据表明感染后其后遗症的持续时间超过1年。目前在西非疫情的严重性关于其健康的影响及未来这些患者的医疗需求更需要完整的理解。方法:疫情暴发后的29个月,我们邀请2007年乌干达本迪布焦埃博拉病毒疫情成人幸存者和他们的联系人参加了一项观察性研究。我们收集关于健康状况,功能限制和人口统计数据方面的信息。我们采用ELISA法收集临床化学、血液学和线状病毒抗体的血液

Nat Commun:重大突破——终身有效的流感疫苗

如果只需要注射一次疫苗就可以终身不得流感,这该多好啊。现在科学家们似乎找到了制造这种疫苗的关键。 复旦大学和墨尔本大学的研究人员发现,有一种杀死流感的免疫细胞可以记住病毒株。这项研究发表在五月十三日的 Nature Communications 杂志上,文章的通讯作者是复旦大学的徐建青(Jianqing Xu)研究员和墨尔本大学的Katherine Kedzierska。

Baidu
map
Baidu
map
Baidu
map